Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yinhua Miyanling versus levofloxacin for uncomplicated urinary tract infection and recurrent urinary tract infection flare
ChiCTR2200066312Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Yinhua Miyanling and levofloxacin in urinary tract infection (UTI) (4 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Proportion of patients treated with additional antimicrobials for UTI from V0 to V3. Started Dec 2022; status: recruiting.
02
Drugs
Yinhua Miyanlinglevofloxacin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on ChiCTR2200066312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066312.